Journey Medical (DERM) Depreciation & Amortization (CF) (2020)

Journey Medical (DERM) posted Depreciation & Amortization (CF) of $1000.0 for Q4 2020, little changed on a QoQ basis from $1000.0 in Q3 2020.

Journey Medical (DERM) Depreciation & Amortization (CF) (2020) Analysis & Trends

Journey Medical's Depreciation & Amortization (CF) history runs 1 years deep, the most recent figure standing at $1000.0 for Q4 2020.

Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $1000.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $1000.0 (changed N/A YoY) and the FY2020 annual result came in at $5000.0, changed N/A from the prior year.
Depreciation & Amortization (CF) was $1000.0 for Q4 2020 at Journey Medical, roughly flat from $1000.0 in the prior quarter.
Across five years, Depreciation & Amortization (CF) topped out at $1000.0 in Q3 2020 and bottomed at $1000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Depreciation & Amortization (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	239.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	119.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	1.04 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	22.60 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	676.10 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	7.20 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	172.00 Mn
10	Journey Medical	179.67 Mn	152.45 Mn	9.70 Mn	-

Download Data